Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol + citrate + simeticone + bisacodyl (also known as PEG-CS plus bisacodyl) is a low-volume bowel preparation regimen primarily indicated for colonic cleansing prior to colonoscopy or computed tomography colonography (CTC). The formulation consists of a 2-liter polyethylene glycol (PEG) solution enriched with citrates and simethicone, administered in conjunction with bisacodyl tablets. The components work through distinct yet complementary mechanisms: PEG and citrates act as osmotic laxatives to increase intestinal water retention and stool volume; bisacodyl serves as a stimulant laxative to enhance colonic motility; and simethicone acts as an anti-foaming agent to eliminate gas bubbles that might otherwise obscure visualization during endoscopic procedures. This combination is designed to provide equivalent bowel cleansing efficacy to traditional 4-liter PEG preparations while significantly improving patient tolerability, compliance, and overall acceptability due to the reduced fluid volume.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on macrogol + citrate + simeticone + bisacodyl.